{"name":"Chong Kun Dang Pharmaceutical","slug":"chong-kun-dang-pharmaceutical","ticker":"","exchange":"","domain":"chongkundang.com","description":"","hq":"Seoul","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":70,"colorKey":"oncology","drugs":[{"name":"D745 formulation II","genericName":"D745 formulation II","slug":"d745-formulation-ii","indication":"Phase 3 clinical trials for D745 formulation II are ongoing, but the exact indications are not publicly disclosed.","status":"phase_3"},{"name":"CKD-333 formulation I","genericName":"CKD-333 formulation I","slug":"ckd-333-formulation-i","indication":"Other","status":"phase_1"},{"name":"CKD-348 F1","genericName":"CKD-348 F1","slug":"ckd-348-f1","indication":"Other","status":"phase_1"},{"name":"CKD-390","genericName":"CKD-390","slug":"ckd-390","indication":"Other","status":"phase_3"},{"name":"CKD-828 Formulation 2","genericName":"CKD-828 Formulation 2","slug":"ckd-828-formulation-2","indication":"Other","status":"phase_1"},{"name":"CKD-841 A-1 1.88mg","genericName":"CKD-841 A-1 1.88mg","slug":"ckd-841-a-1-1-88mg","indication":"Other","status":"phase_1"},{"name":"Cantabell Tab","genericName":"Cantabell Tab","slug":"cantabell-tab","indication":"Gastrointestinal spasms and cramping","status":"marketed"},{"name":"D013, D326, D337","genericName":"D013, D326, D337","slug":"d013-d326-d337","indication":"Other","status":"phase_3"},{"name":"D013, placebo of D326, placebo of D337","genericName":"D013, placebo of D326, placebo of D337","slug":"d013-placebo-of-d326-placebo-of-d337","indication":"Other","status":"phase_3"},{"name":"D113","genericName":"D113","slug":"d113","indication":"Other","status":"phase_1"},{"name":"D309","genericName":"D309","slug":"d309","indication":"Other","status":"phase_1"},{"name":"D326(placebo)","genericName":"D326(placebo)","slug":"d326-placebo","indication":"Other","status":"phase_3"},{"name":"D337(placebo)","genericName":"D337(placebo)","slug":"d337-placebo","indication":"Other","status":"phase_3"},{"name":"Imotun","genericName":"Imotun","slug":"imotun","indication":"Other","status":"marketed"},{"name":"Tacrolimus cap.","genericName":"Tacrolimus cap.","slug":"tacrolimus-cap","indication":"Other","status":"marketed"},{"name":"Baraclude Tab. 0.5mg","genericName":"Baraclude Tab. 0.5mg","slug":"baraclude-tab-0-5mg","indication":"Other","status":"marketed"},{"name":"CKD-11101","genericName":"CKD-11101","slug":"ckd-11101","indication":"Other","status":"phase_3"},{"name":"CKD-330","genericName":"CKD-330","slug":"ckd-330","indication":"Other","status":"phase_3"},{"name":"CKD-333 Tab.","genericName":"CKD-333 Tab.","slug":"ckd-333-tab","indication":"Other","status":"phase_1"},{"name":"CKD-333 formulation II","genericName":"CKD-333 formulation II","slug":"ckd-333-formulation-ii","indication":"Other","status":"phase_1"},{"name":"CKD-333, formula II","genericName":"CKD-333, formula II","slug":"ckd-333-formula-ii","indication":"Other","status":"phase_1"},{"name":"CKD-341","genericName":"CKD-341","slug":"ckd-341","indication":"Other","status":"phase_1"},{"name":"CKD-348 T2, CKD-348 T1, CKD-828, D097, D337","genericName":"CKD-348 T2, CKD-348 T1, CKD-828, D097, D337","slug":"ckd-348-t2-ckd-348-t1-ckd-828-d097-d337","indication":"Other","status":"phase_1"},{"name":"CKD-379 II","genericName":"CKD-379 II","slug":"ckd-379-ii","indication":"Other","status":"phase_1"},{"name":"CKD-498 dose#1","genericName":"CKD-498 dose#1","slug":"ckd-498-dose-1","indication":"Other","status":"phase_2"},{"name":"CKD-501, D759, H053","genericName":"CKD-501, D759, H053","slug":"ckd-501-d759-h053","indication":"Other","status":"phase_1"},{"name":"CKD-702","genericName":"CKD-702","slug":"ckd-702","indication":"Other","status":"phase_1"},{"name":"CKD-706","genericName":"CKD-706","slug":"ckd-706","indication":"Other","status":"phase_1"},{"name":"CKD-828(placebo)","genericName":"CKD-828(placebo)","slug":"ckd-828-placebo","indication":"Other","status":"phase_3"},{"name":"Chong Kun Dang Tamsulosin HCl Tab.","genericName":"Chong Kun Dang Tamsulosin HCl Tab.","slug":"chong-kun-dang-tamsulosin-hcl-tab","indication":"Other","status":"phase_1"},{"name":"Cialis Tab. 5mg","genericName":"Cialis Tab. 5mg","slug":"cialis-tab-5mg","indication":"Other","status":"phase_1"},{"name":"Conversion to Once-daily Tacrolimus","genericName":"Conversion to Once-daily Tacrolimus","slug":"conversion-to-once-daily-tacrolimus","indication":"Other","status":"marketed"},{"name":"D012, placebo of D064, placebo of D701","genericName":"D012, placebo of D064, placebo of D701","slug":"d012-placebo-of-d064-placebo-of-d701","indication":"Other","status":"phase_3"},{"name":"D013(placebo)","genericName":"D013(placebo)","slug":"d013-placebo","indication":"Other","status":"phase_3"},{"name":"D064 and D702, QD","genericName":"D064 and D702, QD","slug":"d064-and-d702-qd","indication":"Other","status":"phase_3"},{"name":"D064 and Placebo of D702, QD","genericName":"D064 and Placebo of D702, QD","slug":"d064-and-placebo-of-d702-qd","indication":"Other","status":"phase_3"},{"name":"D064, D701, placebo of D012","genericName":"D064, D701, placebo of D012","slug":"d064-d701-placebo-of-d012","indication":"Other","status":"phase_3"},{"name":"D064, D702, placebo of D660","genericName":"D064, D702, placebo of D660","slug":"d064-d702-placebo-of-d660","indication":"Other","status":"phase_3"},{"name":"D326, D337 and D013","genericName":"D326, D337 and D013","slug":"d326-d337-and-d013","indication":"Other","status":"phase_1"},{"name":"D337","genericName":"D337","slug":"d337","indication":"Other","status":"phase_3"},{"name":"D377","genericName":"D377","slug":"d377","indication":"Other","status":"phase_3"},{"name":"D660, placebo of D064, placebo of D702","genericName":"D660, placebo of D064, placebo of D702","slug":"d660-placebo-of-d064-placebo-of-d702","indication":"Other","status":"phase_3"},{"name":"D723","genericName":"D723","slug":"d723","indication":"Other","status":"phase_3"},{"name":"D745 formulation I","genericName":"D745 formulation I","slug":"d745-formulation-i","indication":"Indication 1","status":"phase_3"},{"name":"D930","genericName":"D930","slug":"d930","indication":"Other","status":"phase_3"},{"name":"EsoDuo® Tablet","genericName":"EsoDuo® Tablet","slug":"esoduo-tablet","indication":"Other","status":"marketed"},{"name":"Eupasidin-s Tab","genericName":"Eupasidin-s Tab","slug":"eupasidin-s-tab","indication":"Other","status":"marketed"},{"name":"Januvia Tab. 100mg","genericName":"Januvia Tab. 100mg","slug":"januvia-tab-100mg","indication":"Other","status":"phase_1"},{"name":"Levocabastine HCL","genericName":"Levocabastine HCL","slug":"levocabastine-hcl","indication":"Allergic rhinitis","status":"phase_3"},{"name":"Memantine Tab. 10mg","genericName":"Memantine Tab. 10mg","slug":"memantine-tab-10mg","indication":"Other","status":"phase_1"},{"name":"Myreptic-N Tablet","genericName":"Myreptic-N Tablet","slug":"myreptic-n-tablet","indication":"Other","status":"marketed"},{"name":"Placebo (for CKD-331)","genericName":"Placebo (for CKD-331)","slug":"placebo-for-ckd-331","indication":"Other","status":"phase_3"},{"name":"Placebo (for D086)","genericName":"Placebo (for D086)","slug":"placebo-for-d086","indication":"Control arm in phase 3 trial for D086 (indication unknown)","status":"phase_3"},{"name":"Placebo (for D377)","genericName":"Placebo (for D377)","slug":"placebo-for-d377","indication":"Other","status":"phase_3"},{"name":"Placebo of CKD-330","genericName":"Placebo of CKD-330","slug":"placebo-of-ckd-330","indication":"Other","status":"phase_3"},{"name":"Placebo of CKD-351","genericName":"Placebo of CKD-351","slug":"placebo-of-ckd-351","indication":"Other","status":"phase_3"},{"name":"Placebo of CKD-843 dose","genericName":"Placebo of CKD-843 dose","slug":"placebo-of-ckd-843-dose","indication":"Other","status":"phase_3"},{"name":"Placebo of D064 and D702, QD","genericName":"Placebo of D064 and D702, QD","slug":"placebo-of-d064-and-d702-qd","indication":"Other","status":"phase_3"},{"name":"Placebo of D086","genericName":"Placebo of D086","slug":"placebo-of-d086","indication":"Treatment of symptoms associated with a clinical trial","status":"phase_3"},{"name":"Placebo of D723","genericName":"Placebo of D723","slug":"placebo-of-d723","indication":"Other","status":"phase_3"},{"name":"Placebo of D930","genericName":"Placebo of D930","slug":"placebo-of-d930","indication":"Treatment of symptoms associated with a clinical trial","status":"phase_3"},{"name":"Placebo of Dutasteride Capsule","genericName":"Placebo of Dutasteride Capsule","slug":"placebo-of-dutasteride-capsule","indication":"Other","status":"phase_3"},{"name":"Prograf capsule 1mg","genericName":"Prograf capsule 1mg","slug":"prograf-capsule-1mg","indication":"Other","status":"phase_1"},{"name":"TELMINUVO Tab. (80/5mg)","genericName":"TELMINUVO Tab. (80/5mg)","slug":"telminuvo-tab-80-5mg","indication":"Phase 3 for unspecified indication","status":"phase_3"},{"name":"Tacrolimus with Methotrexate","genericName":"Tacrolimus with Methotrexate","slug":"tacrolimus-with-methotrexate","indication":"Other","status":"marketed"},{"name":"Xenobella","genericName":"Xenobella","slug":"xenobella","indication":"Other","status":"phase_3"},{"name":"amlodiopine","genericName":"amlodiopine","slug":"amlodiopine","indication":"Other","status":"phase_1"},{"name":"empagliflozin 10mg","genericName":"empagliflozin 10mg","slug":"empagliflozin-10mg","indication":"Other","status":"marketed"},{"name":"placebo of D013, D326, D337","genericName":"placebo of D013, D326, D337","slug":"placebo-of-d013-d326-d337","indication":"Other","status":"phase_3"},{"name":"tacrolimus capsules","genericName":"tacrolimus capsules","slug":"tacrolimus-capsules","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"immunology","drugs":[{"name":"CKD-342","genericName":"CKD-342","slug":"ckd-342","indication":"Hormone receptor-positive, HER2-negative breast cancer","status":"phase_3"},{"name":"CKD-701","genericName":"CKD-701","slug":"ckd-701","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"Everolimus Tab.","genericName":"Everolimus Tab.","slug":"everolimus-tab","indication":"Advanced renal cell carcinoma","status":"marketed"},{"name":"CKD-11101(Darbepoetin alfa)","genericName":"CKD-11101(Darbepoetin alfa)","slug":"ckd-11101-darbepoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"CKD-331","genericName":"CKD-331","slug":"ckd-331","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"CKD-351","genericName":"CKD-351","slug":"ckd-351","indication":"Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"CKD-352","genericName":"CKD-352","slug":"ckd-352","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"CKD-825","genericName":"CKD-825","slug":"ckd-825","indication":"Hormone receptor-positive, HER2-negative breast cancer","status":"phase_3"},{"name":"CKD-828","genericName":"CKD-828","slug":"ckd-828","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"CKD-843 dose#1","genericName":"CKD-843 dose#1","slug":"ckd-843-dose-1","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"NESP(Darbepoetin alfa)","genericName":"NESP(Darbepoetin alfa)","slug":"nesp-darbepoetin-alfa","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Sirolimus Tab.","genericName":"Sirolimus Tab.","slug":"sirolimus-tab","indication":"Prophylaxis of organ rejection in patients receiving renal transplants","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"cardiovascular","drugs":[{"name":"Candemore Plus Tab","genericName":"Candemore Plus Tab","slug":"candemore-plus-tab","indication":"Hypertension","status":"marketed"},{"name":"D086","genericName":"D086","slug":"d086","indication":"Hypertension","status":"phase_3"},{"name":"Atorvastatin (Lipilou)","genericName":"Atorvastatin (Lipilou)","slug":"atorvastatin-lipilou","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"},{"name":"Candemore tablet","genericName":"Candemore tablet","slug":"candemore-tablet","indication":"Essential hypertension","status":"marketed"},{"name":"Carvedilol IR 25mg, BID","genericName":"Carvedilol IR 25mg, BID","slug":"carvedilol-ir-25mg-bid","indication":"Heart failure with reduced ejection fraction","status":"phase_3"},{"name":"Carvedilol IR 25mg, QD","genericName":"Carvedilol IR 25mg, QD","slug":"carvedilol-ir-25mg-qd","indication":"Heart failure with reduced ejection fraction","status":"phase_3"},{"name":"Carvedilol SR 32mg, QD","genericName":"Carvedilol SR 32mg, QD","slug":"carvedilol-sr-32mg-qd","indication":"Hypertension","status":"phase_3"},{"name":"Carvedilol SR 64mg, QD","genericName":"Carvedilol SR 64mg, QD","slug":"carvedilol-sr-64mg-qd","indication":"Heart failure with reduced ejection fraction","status":"phase_3"},{"name":"Cozzar tablet","genericName":"Cozzar tablet","slug":"cozzar-tablet","indication":"Hypertension","status":"marketed"},{"name":"Nafamostat Mesilate","genericName":"Nafamostat Mesilate","slug":"nafamostat-mesilate","indication":"Anticoagulation during hemodialysis and extracorporeal circulation","status":"marketed"},{"name":"TELMINUVO Tab. (80/2.5mg)","genericName":"TELMINUVO Tab. (80/2.5mg)","slug":"telminuvo-tab-80-2-5mg","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Atrovastatin and Ezetimibe combination therapy","genericName":"Atrovastatin and Ezetimibe combination therapy","slug":"atrovastatin-and-ezetimibe-combination-therapy","indication":"Hypercholesterolemia","status":"phase_1"},{"name":"CKD-314+SOC","genericName":"CKD-314+SOC","slug":"ckd-314-soc","indication":"Type 2 diabetes mellitus (as add-on to standard of care)","status":"phase_3"},{"name":"CKD-498 dose#2","genericName":"CKD-498 dose#2","slug":"ckd-498-dose-2","indication":"Type 2 diabetes","status":"phase_2"},{"name":"CKD-498 dose#3","genericName":"CKD-498 dose#3","slug":"ckd-498-dose-3","indication":"Type 2 diabetes","status":"phase_2"},{"name":"CKD-843 dose#2","genericName":"CKD-843 dose#2","slug":"ckd-843-dose-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"D013","genericName":"D013","slug":"d013","indication":"Type 2 diabetes","status":"phase_3"},{"name":"D326","genericName":"D326","slug":"d326","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"infectious","drugs":[{"name":"Methylprednisolone/prednisolone","genericName":"Methylprednisolone/prednisolone","slug":"methylprednisolone-prednisolone","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)","status":"marketed"},{"name":"Mycophenolate mofetil Tab./Cap.","genericName":"Mycophenolate mofetil Tab./Cap.","slug":"mycophenolate-mofetil-tab-cap","indication":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","status":"marketed"},{"name":"Mycophenolate mofetil Tablet/Capsule","genericName":"Mycophenolate mofetil Tablet/Capsule","slug":"mycophenolate-mofetil-tablet-capsule","indication":"Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants","status":"marketed"},{"name":"Mycophenolate Mofetil Cap./Tab.","genericName":"Mycophenolate Mofetil Cap./Tab.","slug":"mycophenolate-mofetil-cap-tab","indication":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","status":"marketed"},{"name":"SKYRIZI","genericName":"SKYRIZI","slug":"skyrizi","indication":"Moderate to severe plaque psoriasis","status":"marketed"},{"name":"TacroBell SR cap.","genericName":"TacroBell SR cap.","slug":"tacrobell-sr-cap","indication":"Organ transplant rejection prophylaxis (renal, cardiac, hepatic)","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Isotonic 0.3% Sodium Hyaluronate","genericName":"Isotonic 0.3% Sodium Hyaluronate","slug":"isotonic-0-3-sodium-hyaluronate","indication":"Dry eye syndrome / Keratoconjunctivitis sicca","status":"phase_3"}]}],"pipeline":[{"name":"D745 formulation II","genericName":"D745 formulation II","slug":"d745-formulation-ii","phase":"phase_3","mechanism":"D745 formulation II is a drug that targets the molecular target to exert its therapeutic effect.","indications":["Phase 3 clinical trials for D745 formulation II are ongoing, but the exact indications are not publicly disclosed."],"catalyst":""},{"name":"CKD-333 formulation I","genericName":"CKD-333 formulation I","slug":"ckd-333-formulation-i","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-342","genericName":"CKD-342","slug":"ckd-342","phase":"phase_3","mechanism":"CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative breast cancer"],"catalyst":""},{"name":"CKD-348 F1","genericName":"CKD-348 F1","slug":"ckd-348-f1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-390","genericName":"CKD-390","slug":"ckd-390","phase":"phase_3","mechanism":"CKD-390 is a small molecule inhibitor targeting a specific cellular pathway involved in inflammatory or metabolic disease.","indications":[],"catalyst":""},{"name":"CKD-701","genericName":"CKD-701","slug":"ckd-701","phase":"phase_3","mechanism":"CKD-701 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"CKD-828 Formulation 2","genericName":"CKD-828 Formulation 2","slug":"ckd-828-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-841 A-1 1.88mg","genericName":"CKD-841 A-1 1.88mg","slug":"ckd-841-a-1-1-88mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candemore Plus Tab","genericName":"Candemore Plus Tab","slug":"candemore-plus-tab","phase":"marketed","mechanism":"Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.","indications":["Hypertension"],"catalyst":""},{"name":"Cantabell Tab","genericName":"Cantabell Tab","slug":"cantabell-tab","phase":"marketed","mechanism":"Cantabell is an antispasmodic agent that relaxes smooth muscle in the gastrointestinal and urinary tracts by blocking muscarinic acetylcholine receptors.","indications":["Gastrointestinal spasms and cramping","Irritable bowel syndrome (IBS)","Urinary incontinence and urinary urgency"],"catalyst":""},{"name":"D013, D326, D337","genericName":"D013, D326, D337","slug":"d013-d326-d337","phase":"phase_3","mechanism":"D013, D326, and D337 are investigational drugs with unknown mechanisms of action.","indications":[],"catalyst":""},{"name":"D013, placebo of D326, placebo of D337","genericName":"D013, placebo of D326, placebo of D337","slug":"d013-placebo-of-d326-placebo-of-d337","phase":"phase_3","mechanism":"D013 is a placebo control formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"D086","genericName":"D086","slug":"d086","phase":"phase_3","mechanism":"D086 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism.","indications":["Hypertension"],"catalyst":""},{"name":"D113","genericName":"D113","slug":"d113","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"D309","genericName":"D309","slug":"d309","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"D326(placebo)","genericName":"D326(placebo)","slug":"d326-placebo","phase":"phase_3","mechanism":"D326 is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"D337(placebo)","genericName":"D337(placebo)","slug":"d337-placebo","phase":"phase_3","mechanism":"D337 is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Everolimus Tab.","genericName":"Everolimus Tab.","slug":"everolimus-tab","phase":"marketed","mechanism":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","indications":["Advanced renal cell carcinoma","Breast cancer (hormone receptor-positive, HER2-negative)","Neuroendocrine tumors of pancreatic origin","Subependymal giant cell astrocytoma (SEGA)","Renal angiomyolipoma associated with tuberous sclerosis complex"],"catalyst":""},{"name":"Imotun","genericName":"Imotun","slug":"imotun","phase":"marketed","mechanism":"Specific signaling molecules","indications":[],"catalyst":""},{"name":"Isotonic 0.3% Sodium Hyaluronate","genericName":"Isotonic 0.3% Sodium Hyaluronate","slug":"isotonic-0-3-sodium-hyaluronate","phase":"phase_3","mechanism":"Sodium hyaluronate is a viscoelastic substance that lubricates and protects ocular surfaces by mimicking natural tear film components.","indications":["Dry eye syndrome / Keratoconjunctivitis sicca","Ocular surface protection and lubrication"],"catalyst":""},{"name":"Methylprednisolone/prednisolone","genericName":"Methylprednisolone/prednisolone","slug":"methylprednisolone-prednisolone","phase":"marketed","mechanism":"Methylprednisolone and prednisolone are corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, vasculitis)","Allergic reactions and asthma exacerbations","Adrenal insufficiency","Cerebral edema","Organ transplant rejection prophylaxis"],"catalyst":""},{"name":"Mycophenolate mofetil Tab./Cap.","genericName":"Mycophenolate mofetil Tab./Cap.","slug":"mycophenolate-mofetil-tab-cap","phase":"marketed","mechanism":"Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation.","indications":["Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","Active lupus nephritis","Active rheumatoid arthritis (as adjunctive therapy)"],"catalyst":""},{"name":"Mycophenolate mofetil Tablet/Capsule","genericName":"Mycophenolate mofetil Tablet/Capsule","slug":"mycophenolate-mofetil-tablet-capsule","phase":"marketed","mechanism":"Mycophenolate mofetil is a prodrug that inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation.","indications":["Prevention of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants","Treatment of active lupus nephritis"],"catalyst":""},{"name":"Tacrolimus cap.","genericName":"Tacrolimus cap.","slug":"tacrolimus-cap","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atorvastatin (Lipilou)","genericName":"Atorvastatin (Lipilou)","slug":"atorvastatin-lipilou","phase":"marketed","mechanism":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.","indications":["Hypercholesterolemia and dyslipidemia","Primary and secondary prevention of cardiovascular disease","Reduction of risk of myocardial infarction and stroke"],"catalyst":""},{"name":"Atrovastatin and Ezetimibe combination therapy","genericName":"Atrovastatin and Ezetimibe combination therapy","slug":"atrovastatin-and-ezetimibe-combination-therapy","phase":"phase_1","mechanism":"Inhibits HMG-CoA reductase and inhibits cholesterol absorption","indications":["Hypercholesterolemia","Mixed dyslipidemia"],"catalyst":""},{"name":"Baraclude Tab. 0.5mg","genericName":"Baraclude Tab. 0.5mg","slug":"baraclude-tab-0-5mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-11101","genericName":"CKD-11101","slug":"ckd-11101","phase":"phase_3","mechanism":"CKD-11101 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not yet publicly disclosed.","indications":[],"catalyst":""},{"name":"CKD-11101(Darbepoetin alfa)","genericName":"CKD-11101(Darbepoetin alfa)","slug":"ckd-11101-darbepoetin-alfa","phase":"phase_3","mechanism":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia in cancer patients"],"catalyst":""},{"name":"CKD-314+SOC","genericName":"CKD-314+SOC","slug":"ckd-314-soc","phase":"phase_3","mechanism":"CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care.","indications":["Type 2 diabetes mellitus (as add-on to standard of care)"],"catalyst":""},{"name":"CKD-330","genericName":"CKD-330","slug":"ckd-330","phase":"phase_3","mechanism":"CKD-330 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not publicly disclosed in standard references.","indications":[],"catalyst":""},{"name":"CKD-331","genericName":"CKD-331","slug":"ckd-331","phase":"phase_3","mechanism":"CKD-331 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"CKD-333 Tab.","genericName":"CKD-333 Tab.","slug":"ckd-333-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-333 formulation II","genericName":"CKD-333 formulation II","slug":"ckd-333-formulation-ii","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-333, formula II","genericName":"CKD-333, formula II","slug":"ckd-333-formula-ii","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-341","genericName":"CKD-341","slug":"ckd-341","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-348 T2, CKD-348 T1, CKD-828, D097, D337","genericName":"CKD-348 T2, CKD-348 T1, CKD-828, D097, D337","slug":"ckd-348-t2-ckd-348-t1-ckd-828-d097-d337","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-351","genericName":"CKD-351","slug":"ckd-351","phase":"phase_3","mechanism":"CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"CKD-352","genericName":"CKD-352","slug":"ckd-352","phase":"phase_3","mechanism":"CKD-352 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"CKD-379 II","genericName":"CKD-379 II","slug":"ckd-379-ii","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-498 dose#1","genericName":"CKD-498 dose#1","slug":"ckd-498-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-498 dose#2","genericName":"CKD-498 dose#2","slug":"ckd-498-dose-2","phase":"phase_2","mechanism":"CKD-498 dose#2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CKD-498 dose#3","genericName":"CKD-498 dose#3","slug":"ckd-498-dose-3","phase":"phase_2","mechanism":"CKD-498 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CKD-501, D759, H053","genericName":"CKD-501, D759, H053","slug":"ckd-501-d759-h053","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-702","genericName":"CKD-702","slug":"ckd-702","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-706","genericName":"CKD-706","slug":"ckd-706","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CKD-825","genericName":"CKD-825","slug":"ckd-825","phase":"phase_3","mechanism":"CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative breast cancer"],"catalyst":""},{"name":"CKD-828","genericName":"CKD-828","slug":"ckd-828","phase":"phase_3","mechanism":"CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"CKD-828(placebo)","genericName":"CKD-828(placebo)","slug":"ckd-828-placebo","phase":"phase_3","mechanism":"CKD-828 is a placebo control used in clinical trials and has no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"CKD-843 dose#1","genericName":"CKD-843 dose#1","slug":"ckd-843-dose-1","phase":"phase_3","mechanism":"CKD-843 is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"CKD-843 dose#2","genericName":"CKD-843 dose#2","slug":"ckd-843-dose-2","phase":"phase_3","mechanism":"CKD-843 is a selective PPAR-gamma agonist that enhances insulin sensitivity and reduces inflammation.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Candemore tablet","genericName":"Candemore tablet","slug":"candemore-tablet","phase":"marketed","mechanism":"Candemore is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce vasoconstriction and lower blood pressure.","indications":["Essential hypertension","Heart failure with reduced ejection fraction"],"catalyst":""},{"name":"Carvedilol IR 25mg, BID","genericName":"Carvedilol IR 25mg, BID","slug":"carvedilol-ir-25mg-bid","phase":"phase_3","mechanism":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","indications":["Heart failure with reduced ejection fraction","Hypertension","Angina pectoris","Post-myocardial infarction"],"catalyst":""},{"name":"Carvedilol IR 25mg, QD","genericName":"Carvedilol IR 25mg, QD","slug":"carvedilol-ir-25mg-qd","phase":"phase_3","mechanism":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","indications":["Heart failure with reduced ejection fraction","Hypertension","Angina pectoris","Post-myocardial infarction"],"catalyst":""},{"name":"Carvedilol SR 32mg, QD","genericName":"Carvedilol SR 32mg, QD","slug":"carvedilol-sr-32mg-qd","phase":"phase_3","mechanism":"Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","indications":["Hypertension","Heart failure with reduced ejection fraction","Post-myocardial infarction left ventricular dysfunction","Angina pectoris"],"catalyst":""},{"name":"Carvedilol SR 64mg, QD","genericName":"Carvedilol SR 64mg, QD","slug":"carvedilol-sr-64mg-qd","phase":"phase_3","mechanism":"Carvedilol SR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","indications":["Heart failure with reduced ejection fraction","Hypertension","Post-myocardial infarction","Left ventricular dysfunction"],"catalyst":""},{"name":"Chong Kun Dang Tamsulosin HCl Tab.","genericName":"Chong Kun Dang Tamsulosin HCl Tab.","slug":"chong-kun-dang-tamsulosin-hcl-tab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cialis Tab. 5mg","genericName":"Cialis Tab. 5mg","slug":"cialis-tab-5mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Conversion to Once-daily Tacrolimus","genericName":"Conversion to Once-daily Tacrolimus","slug":"conversion-to-once-daily-tacrolimus","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cozzar tablet","genericName":"Cozzar tablet","slug":"cozzar-tablet","phase":"marketed","mechanism":"Cozzar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes","Heart failure"],"catalyst":""},{"name":"D012, placebo of D064, placebo of D701","genericName":"D012, placebo of D064, placebo of D701","slug":"d012-placebo-of-d064-placebo-of-d701","phase":"phase_3","mechanism":"D012 is a placebo control formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"D013","genericName":"D013","slug":"d013","phase":"phase_3","mechanism":"D013 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"D013(placebo)","genericName":"D013(placebo)","slug":"d013-placebo","phase":"phase_3","mechanism":"D013 is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"D064 and D702, QD","genericName":"D064 and D702, QD","slug":"d064-and-d702-qd","phase":"phase_3","mechanism":"D064 and D702 are a fixed-dose combination targeting dual pathways in metabolic or inflammatory disease, though the specific molecular targets are not publicly disclosed.","indications":[],"catalyst":""},{"name":"D064 and Placebo of D702, QD","genericName":"D064 and Placebo of D702, QD","slug":"d064-and-placebo-of-d702-qd","phase":"phase_3","mechanism":"Unfortunately, no information is available on the mechanism of action of D064.","indications":[],"catalyst":""},{"name":"D064, D701, placebo of D012","genericName":"D064, D701, placebo of D012","slug":"d064-d701-placebo-of-d012","phase":"phase_3","mechanism":"This drug is a small molecule.","indications":[],"catalyst":""},{"name":"D064, D702, placebo of D660","genericName":"D064, D702, placebo of D660","slug":"d064-d702-placebo-of-d660","phase":"phase_3","mechanism":"This drug is a small molecule.","indications":[],"catalyst":""},{"name":"D326","genericName":"D326","slug":"d326","phase":"phase_3","mechanism":"D326 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"D326, D337 and D013","genericName":"D326, D337 and D013","slug":"d326-d337-and-d013","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"D337","genericName":"D337","slug":"d337","phase":"phase_3","mechanism":"D337 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"D377","genericName":"D377","slug":"d377","phase":"phase_3","mechanism":"D377 is an investigational therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical.","indications":[],"catalyst":""},{"name":"D660, placebo of D064, placebo of D702","genericName":"D660, placebo of D064, placebo of D702","slug":"d660-placebo-of-d064-placebo-of-d702","phase":"phase_3","mechanism":"D660 is a placebo control formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"D723","genericName":"D723","slug":"d723","phase":"phase_3","mechanism":"D723 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"D745 formulation I","genericName":"D745 formulation I","slug":"d745-formulation-i","phase":"phase_3","mechanism":"D745 formulation I is a small molecule that targets the molecular target.","indications":["Indication 1"],"catalyst":""},{"name":"D930","genericName":"D930","slug":"d930","phase":"phase_3","mechanism":"D930 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"EsoDuo® Tablet","genericName":"EsoDuo® Tablet","slug":"esoduo-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eupasidin-s Tab","genericName":"Eupasidin-s Tab","slug":"eupasidin-s-tab","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Januvia Tab. 100mg","genericName":"Januvia Tab. 100mg","slug":"januvia-tab-100mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Levocabastine HCL","genericName":"Levocabastine HCL","slug":"levocabastine-hcl","phase":"phase_3","mechanism":"Levocabastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","indications":["Allergic rhinitis","Allergic conjunctivitis"],"catalyst":""},{"name":"Memantine Tab. 10mg","genericName":"Memantine Tab. 10mg","slug":"memantine-tab-10mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mycophenolate Mofetil Cap./Tab.","genericName":"Mycophenolate Mofetil Cap./Tab.","slug":"mycophenolate-mofetil-cap-tab","phase":"marketed","mechanism":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.","indications":["Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients","Treatment of active lupus nephritis","Treatment of active rheumatoid arthritis (in combination with other agents)"],"catalyst":""},{"name":"Myreptic-N Tablet","genericName":"Myreptic-N Tablet","slug":"myreptic-n-tablet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NESP(Darbepoetin alfa)","genericName":"NESP(Darbepoetin alfa)","slug":"nesp-darbepoetin-alfa","phase":"phase_3","mechanism":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia in cancer patients","Anemia in patients with non-myeloid malignancies"],"catalyst":""},{"name":"Nafamostat Mesilate","genericName":"Nafamostat Mesilate","slug":"nafamostat-mesilate","phase":"marketed","mechanism":"Nafamostat mesilate is a serine protease inhibitor that blocks multiple coagulation and inflammatory proteases to prevent thrombosis and inflammation.","indications":["Anticoagulation during hemodialysis and extracorporeal circulation","Acute pancreatitis","Severe COVID-19 (investigational)"],"catalyst":""},{"name":"Placebo (for CKD-331)","genericName":"Placebo (for CKD-331)","slug":"placebo-for-ckd-331","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo (for D086)","genericName":"Placebo (for D086)","slug":"placebo-for-d086","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.","indications":["Control arm in phase 3 trial for D086 (indication unknown)"],"catalyst":""},{"name":"Placebo (for D377)","genericName":"Placebo (for D377)","slug":"placebo-for-d377","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo of CKD-330","genericName":"Placebo of CKD-330","slug":"placebo-of-ckd-330","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of CKD-351","genericName":"Placebo of CKD-351","slug":"placebo-of-ckd-351","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of CKD-843 dose","genericName":"Placebo of CKD-843 dose","slug":"placebo-of-ckd-843-dose","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of D064 and D702, QD","genericName":"Placebo of D064 and D702, QD","slug":"placebo-of-d064-and-d702-qd","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of D086","genericName":"Placebo of D086","slug":"placebo-of-d086","phase":"phase_3","mechanism":"This is a placebo, meaning it has no pharmacological effect.","indications":["Treatment of symptoms associated with a clinical trial"],"catalyst":""},{"name":"Placebo of D723","genericName":"Placebo of D723","slug":"placebo-of-d723","phase":"phase_3","mechanism":"D723 is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo of D930","genericName":"Placebo of D930","slug":"placebo-of-d930","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":["Treatment of symptoms associated with a clinical trial"],"catalyst":""},{"name":"Placebo of Dutasteride Capsule","genericName":"Placebo of Dutasteride Capsule","slug":"placebo-of-dutasteride-capsule","phase":"phase_3","mechanism":"This is a placebo control formulation containing no active pharmaceutical ingredient, used as a comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Prograf capsule 1mg","genericName":"Prograf capsule 1mg","slug":"prograf-capsule-1mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SKYRIZI","genericName":"SKYRIZI","slug":"skyrizi","phase":"marketed","mechanism":"SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.","indications":["Moderate to severe plaque psoriasis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Sirolimus Tab.","genericName":"Sirolimus Tab.","slug":"sirolimus-tab","phase":"marketed","mechanism":"Sirolimus inhibits mTOR (mammalian target of rapamycin), a key signaling protein that controls cell growth and proliferation.","indications":["Prophylaxis of organ rejection in patients receiving renal transplants","Lymphangioleiomyomatosis (LAM)","Tuberous sclerosis complex (TSC)-associated tumors"],"catalyst":""},{"name":"TELMINUVO Tab. (80/2.5mg)","genericName":"TELMINUVO Tab. (80/2.5mg)","slug":"telminuvo-tab-80-2-5mg","phase":"phase_3","mechanism":"Telminuvo is a selective inhibitor of the sodium-activated potassium channel, KCNN4.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"TELMINUVO Tab. (80/5mg)","genericName":"TELMINUVO Tab. (80/5mg)","slug":"telminuvo-tab-80-5mg","phase":"phase_3","mechanism":"Telminuvo's mechanism of action is not well-documented, but it is believed to work by inhibiting a specific molecular target.","indications":["Phase 3 for unspecified indication"],"catalyst":""},{"name":"TacroBell SR cap.","genericName":"TacroBell SR cap.","slug":"tacrobell-sr-cap","phase":"marketed","mechanism":"TacroBell SR is a sustained-release formulation of tacrolimus that suppresses T-cell activation and proliferation by inhibiting calcineurin phosphatase.","indications":["Organ transplant rejection prophylaxis (renal, cardiac, hepatic)","Autoimmune and inflammatory conditions (atopic dermatitis, psoriasis)"],"catalyst":""},{"name":"Tacrolimus with Methotrexate","genericName":"Tacrolimus with Methotrexate","slug":"tacrolimus-with-methotrexate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Xenobella","genericName":"Xenobella","slug":"xenobella","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"amlodiopine","genericName":"amlodiopine","slug":"amlodiopine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"empagliflozin 10mg","genericName":"empagliflozin 10mg","slug":"empagliflozin-10mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"placebo of D013, D326, D337","genericName":"placebo of D013, D326, D337","slug":"placebo-of-d013-d326-d337","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tacrolimus capsules","genericName":"tacrolimus capsules","slug":"tacrolimus-capsules","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOUm0xNUlGV0pyeFZRTGZpbWptQkNTYUc1bEVMUmRvSWN3UU81SHRuN2lnVUo3MFdIRnRZZnhTVUFaUngwbXhEUnNDWG5LWGJtbFVXOEtxQzlyTExtNFJfVnVDRzZvRlNqaDF0eUVRUm9tMFlKVTFCam5yTlBKamc5MdIBlAFBVV95cUxOTmV1WC1HY2VGcXNYQjlJYmtyRzhEVnJadllhVEMwQTE3U0ZlZlh5WGJOLXl1OFJGRWl0b1I4ODNVU2JfczJ5eE00bVVzMnBFRkRzdHk3XzNLM1BBYVlEZndFYzlEelJVekpKRF91MXVrN2V0MmdEVmxqY0E1YTNJV3RaYWJQbm5laC1LRWg1SVhfMkFF?oc=5","date":"2026-03-31","type":"trial","source":"Chosunbiz","summary":"Audit risks rattle Korea’s pharma big three as trials and lawsuits loom - CHOSUNBIZ - Chosunbiz","headline":"Audit risks rattle Korea’s pharma big three as trials and lawsuits loom - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSjNNVUlkNmdDejFMSXBBb1hvMjZEM1k4SGhBaHVuVVF0clZHRFRoQ2tCN0t1VDZySF9EcU10aWR0S0dXeEF0T05ZWWJpYTc5eGtreEZOdFpQakk4SE1ZN0VTTzJUeTZvNlB5TzlKUDEySEhLcU91MmFLSG5NMC1zRDdCSnljMFpy?oc=5","date":"2026-02-19","type":"pipeline","source":"조선일보","summary":"Top Five Pharma Sales Jump 9%, Near 9 Trillion Won - 조선일보","headline":"Top Five Pharma Sales Jump 9%, Near 9 Trillion Won - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBSNXFmSnBsWDZUTm5VMUpTMUxSdkJ6RTRJby1KZ0x1ODg2UEZhYjVxR0VlYUN4aEpzdldkT1JPWWw0Nmc1a3pOV1JOOXJkck9TMGJ4a2xNd0ZXUzluNWZ6YVZodFdzR2pCZ1pUWE9B0gFyQVVfeXFMTkQzdGFmU1FQOENVc2hDbTJHdC1XeTlidUtreVBuU1NFekoxOS1uVEZpcEZmaDJlaXRocHptMmFqMXFCZEd1dm9YWk5QS1lLMm1YVkh0N3A1RVM5RDdCU3Z4Mzhjd0hmeHZfU0RaT1dtVmRR?oc=5","date":"2026-01-14","type":"trial","source":"koreabiomed.com","summary":"Chong Kun Dang wins Europe’s 1st phase 1 trial nod for Dupixent biosimilar - koreabiomed.com","headline":"Chong Kun Dang wins Europe’s 1st phase 1 trial nod for Dupixent biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOW5QZkJ4MU54UU1iUXZna1Z2NjBoVUJFSy1VMGhsSi1JamNWX3FfWTg4d0VPTDliRWRodmppZE94TzRZUG5jMlhrbDRlVHVyQTVxWGRsYlZLZXJzZkwxdU1GRG1lT0RsMEZwWUQ5bEs2dnRxdUM5OWIzYnBEMXJPQjhXUUpqVnI5?oc=5","date":"2025-12-18","type":"pipeline","source":"조선일보","summary":"Chong Kun Dang Invests 2.2T Won in Bio-Pharma R&D Complex - 조선일보","headline":"Chong Kun Dang Invests 2.2T Won in Bio-Pharma R&D Complex - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5ISFhTbF82Z01zZTY2cXJJc3NhN2NyY0MtQVh0M3gwb0JTd1FYMTFjalFWQUpIUnA0SlFXVEhYUDhWV2l6R3VfOTFJMDhTcHRBTWZkNUFIS2RITkRxc2J4aXJTNWN6dkUxdFZ5RTBn0gFyQVVfeXFMUG94TF8wenQ5T2ZydE5idE5LdHl3MUJPX0Z5QzVoNUdveTRLMEdpdDZvR1R3X2ZCRWZfODF2VVdXZFZFLUJLQ1hLSElpX2pSaENpSW05aDdoRkJyZEtMakNxeldVNTBRTkVDSFRTQ1JrU3pB?oc=5","date":"2025-11-03","type":"pipeline","source":"koreabiomed.com","summary":"Chong Kun Dang speeds up new drug development through external hires and internal reorganization - koreabiomed.com","headline":"Chong Kun Dang speeds up new drug development through external hires and internal reorganization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9pWW15QUQyUlZEdDU1ZUkxc3JXNkJabS1jdVlpbVdjcHh5M1IweVZhOHVZQ1pINHEzLWE4RjlydUtZZms5N3ZudGtwc29mOGlZZmFvSFNwZGZhM29pY2ZFcTFrVENqSkpCaW9kSzhn0gFyQVVfeXFMTW9Ka0x1SWhWUFM0QVZHanllSUFLcnhrV0ttOE1fMy1yQ2VkZHlQeEpnUnI5SWRMVjAwT3ZYTFZYMWdBbFZIMmtabE92ZzI0TXJPRU9abm1nUXVJMkx2UTU2eXhMVGNRZ2ZROEdZTHJyMGhn?oc=5","date":"2025-10-29","type":"regulatory","source":"koreabiomed.com","summary":"Chong Kun Dang wins EMA’s nod for Skyrizi biosimilar trial in Europe - koreabiomed.com","headline":"Chong Kun Dang wins EMA’s nod for Skyrizi biosimilar trial in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQUVM4NElXTlNDa2pEOHhpOV9fXzBVMDRVVVpFUFlsSWoyV3JxWXNqNlZvMlpfM01EVWFzUzQ2aEw3Q3dPbWNUTkVweDhFRnc0bk9CV3JBZTRnR0JtQVY4ZGZWMHAtdGJfbkwtZWZTSUYzVzYwSUY1Y0hCaXNRaWFiONIBlAFBVV95cUxNbnJ3aU12Ym1fMUktNjR2OEdMd2RZR2hEYlRha0lvemJzUzFWSWsyRnJMaE8xOEYxc0lCWnhsTXJiUXdOdEpaenQtUENvU0U5N1BUVG9mS1BDdWw5eldadmgzLXNxZ0liTG9tQzRHQV9mTFJJd2JQOGZjUFdQWlYyY1RTeXk0Wi1zdk0zUG1ZM2NFVkcz?oc=5","date":"2025-10-23","type":"pipeline","source":"Chosunbiz","summary":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ - Chosunbiz","headline":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1CNjFQV2RRMGlYdHAzQ2J4TDRYMWIyakNPUERiQkp0X0xPR25QTFp0TUJmbGdjR0FCdG9aUlZjUGFrNWhvbGc1dWhvcHlHTGtLUjZ2QncxU2Z5U01TRVNyZ21GMk1MVVpUdGJ5dGRn0gFyQVVfeXFMTkFnUDVuRFdxQThndmF3Wmgtb2xDc0RteHNqdTU3dmhFdTBjNUkwdmtvWm5NRGwxaU5SbVVDNFBXbWFUOVhkbnlBcE1zb1RUaVRyRnFJbU54em5ITW5TNlI1dV9VZFB0ZmR2Vmh2SERjb0x3?oc=5","date":"2025-10-01","type":"pipeline","source":"koreabiomed.com","summary":"CKD Pharm to exclusively sell Bayer’s chronic heart failure drug Verquvo - koreabiomed.com","headline":"CKD Pharm to exclusively sell Bayer’s chronic heart failure drug Verquvo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFAwbU9pRlg3aGZ0Umw0VHY1RzVHaWQyUDVTT3Q0b3VGZkFnQ3gxM2Y5UGFIa1liLVdrRVR6ZlRfdDdGWUo0Vl82cVVRcmlaTEFlaDFkU09PWXZZa2Vjc2JiVUZ5cHZfNW9TcVVMakFabXd3ZS1H?oc=5","date":"2025-09-18","type":"deal","source":"Businesskorea","summary":"Chong Kun Dang, Novo Nordisk Partner on Obesity Drug - Businesskorea","headline":"Chong Kun Dang, Novo Nordisk Partner on Obesity Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE0yaWp6WXI5UjhuLVhCVkEyUHNrOFZORHRzbDRMZzh2c1BkMjRfRmk0UTd6UDZrUm4walBqUzc1QVNUUEcxdUJLc2RDeXAtR3pueFBMcFpaQkFBdFVQLU9kT3FyR2xLdEdPVl9kQ1ZYSU5QeFNt?oc=5","date":"2025-07-29","type":"deal","source":"Businesskorea","summary":"Novo Nordisk Partners with Chong Kun Dang for ‘Wegovy’ Boost - Businesskorea","headline":"Novo Nordisk Partners with Chong Kun Dang for ‘Wegovy’ Boost","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPbHAweGdhM3Vva0tMRU9IXzdqZ25wSU1ZNXliNjBNc1Fsbk1IaUZLRWRZSnlTMzZ6cFhPRTJZU01HYXV3TkF1b1p6eldhMXJwNGllUVppTXgzNVkyYzlmbUZrQkFHRnRLSXlnUENYUFpacVVYNjU0NHM3QXNxTlNlaEE1QlhoalVBVGFKQjdNRHlGWnVHNkxhRUZ1T3JQSHBvWElB?oc=5","date":"2023-11-07","type":"pipeline","source":"BioSpace","summary":"Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule - BioSpace","headline":"Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBhcUlYeWtzSjBPWkZ0OW1VbEx2M2xENGtTUWhhTnhBUGVqbUJiYVNsN0tNUFYyTDFNR0xMUjIyeE5CaEhKczZ2R0dIaGRMdWEzZjJDX0tlZUdKYUxlR2NfNDZGbzZwNTRkWmkyZHRR?oc=5","date":"2023-11-06","type":"deal","source":"KED Global","summary":"Chong Kun Dang rallies on $1.3 bn deal with Novartis - KED Global","headline":"Chong Kun Dang rallies on $1.3 bn deal with Novartis","sentiment":"neutral"}],"patents":[],"drugCount":107,"phaseCounts":{"phase_3":57,"phase_1":23,"marketed":24,"phase_2":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}